JP2002503946A - サイトカイン、ストレス、および腫瘍性蛋白質によって活性化されるヒトプロテインキナーゼキナーゼ - Google Patents
サイトカイン、ストレス、および腫瘍性蛋白質によって活性化されるヒトプロテインキナーゼキナーゼInfo
- Publication number
- JP2002503946A JP2002503946A JP53478796A JP53478796A JP2002503946A JP 2002503946 A JP2002503946 A JP 2002503946A JP 53478796 A JP53478796 A JP 53478796A JP 53478796 A JP53478796 A JP 53478796A JP 2002503946 A JP2002503946 A JP 2002503946A
- Authority
- JP
- Japan
- Prior art keywords
- mkk
- polynucleotide
- sequence
- atf2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4736—Retinoblastoma protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.セリン、トレオニン、およびチロシンキナーゼ活性を有し、ヒトマイトジェ ン活性化プロテイン(MAP)キナーゼp38をリン酸化する、実質的に純粋なヒトマ イトジェン活性化プロテインキナーゼキナーゼ(MKK)のポリペプチド。 2.配列番号:2のアミノ酸配列を含む、請求項1記載のポリペプチド。 3.請求項2記載のポリペプチドをコードする、単離および精製されたポリヌクレ オチド。 4.配列番号:1の配列もしくはその縮重変異体を含む、単離および精製された請 求項3記載のポリヌクレオチド、または配列番号:1の配列もしくはその縮重変異 体に対して完全に相補的なポリヌクレオチド。 5.厳密なハイブリダイゼーション条件下において配列番号:1の配列とハイブリ ダイズするポリヌクレオチド配列を含む、単離および精製された請求項3記載の ポリヌクレオチド。 6.配列番号:4のアミノ酸配列を含む、請求項1記載のポリペプチド。 7.請求項6記載のポリペプチドをコードする、単離および精製されたポリヌクレ オチド。 8.配列番号:3の配列もしくはその縮重変異体を含む、単離および精製された請 求項3記載のポリヌクレオチド、または配列番号:3の配列もしくはその縮重変異 体に対して完全に相補的なポリヌクレオチド。 9.厳密なハイブリダイゼーション条件下において配列番号:3の配列とハイブリ ダイズするポリヌクレオチド配列を含む、単離および精製された請求項7記載の ポリヌクレオチド。 10.ポリペプチドがヒトマイトジェン活性化プロテイン(MAP)キナーゼJNKをリ ン酸化することをさらに特徴とする、請求項1記載のポリペプチド。 11.配列番号:6のアミノ酸配列を含む、請求項10記載のポリペプチド。 12.請求項11記載のポリペプチドをコードする、単離および精製されたポリヌク レオチド。 13.配列番号:5の配列もしくはその縮重変異体を含む、単離および精製された 請求項12記載のポリヌクレオチド、または配列番号:5の配列もしくはその縮重 変異 体に対して完全に相補的なポリヌクレオチド。 14.厳密なハイブリダイゼーション条件下において配列番号:5の配列とハイブ リダイズするポリヌクレオチド配列を含む、単離および精製された請求項12記載 のポリヌクレオチド。 15.配列番号:8のアミノ酸配列を含む、請求項10記載のポリペプチド。 16.請求項15記載のポリペプチドをコードする、単離および精製されたポリヌク レオチド。 17.配列番号:7の配列もしくはその縮重変異体を含む、単離および精製された 請求項16記載のポリヌクレオチド、または配列番号:7の配列もしくはその縮重 変異体に対して完全に相補的なポリヌクレオチド。 18.厳密なハイブリダイゼーション条件下において配列番号:7の配列とハイブ リダイズするポリヌクレオチド配列を含む、単離および精製された請求項16記載 のポリヌクレオチド。 19.配列番号:10のアミノ酸配列を含む、請求項10記載のポリペプチド。 20.請求項19記載のポリペプチドをコードする、単離および精製されたポリヌク レオチド。 21.配列番号:9の配列もしくはその縮重変異体を含む、単離および精製された 請求項20記載のポリヌクレオチド、または配列番号:9の配列もしくはその縮重 変異体に対して完全に相補的なポリヌクレオチド。 22.請求項3、7、12、16、または20のいずれか一項に記載のポリヌクレオチドを 含む組換え発現ベクター。 23.請求項3、7、12、16、または20のいずれか一項に記載のポリヌクレオチドを 含む組換え宿主細胞。 24.請求項1、2、6、10、11、15、または19のいずれか一項に記載のポリペプチ ドと特異的に結合する精製された抗体。 25.生物学的被験試料におけるマイトジェン活性化プロテインキナーゼキナーゼ (MKK)の活性を測定する方法であって、 a)該被験試料を、請求項1記載のMKKポリペプチドのMKKの基質および標識された リン酸と共に、該基質がリン酸化されるために十分な条件下でインキュベートす る 段階、および b)MKK活性の指標となる、該基質への標識されたリン酸の取り込み速度を決定す る段階 を含む方法。 26.MKKの基質が、p38およびJNK MAPキナーゼ、活性化転写因子-2(ATF2)、ATF a、cAMP応答因子結合蛋白質(CRE-BPa)、ならびにc-Junからなる群より選択さ れる、請求項25記載の方法。 27.生物学的被験試料が、哺乳動物から採取された体液、細胞、または組織であ る、請求項25記載の方法。 28.生物学的被験試料におけるMKKの合成を測定する方法であって、 a)該試料中に存在する蛋白質をゲル電気泳動により分画する段階、 b)蛋白質を膜へ移行させる段階、および c)結合した標識抗体の量によってMKKの合成のレベルが決定される、請求項1記載 のMKKポリペプチドに特異的な標識抗体を用いて蛋白質を探索する段階 を含む方法。 29.被験試料におけるMKKの発現のレベルを測定するための方法であって、 a)被験試料からポリアデニル化されたRNAを単離する段階、 b)ポリアデニル化されたRNAを、請求項1記載のMKKポリペプチドに特異的なポリ ヌクレオチドプローブと共にインキュベートする段階、 c)MKKの発現のレベルが、該RNAとハイブリダイズしたMKKプローブの量と直接的 に関係するような、該ポリアデニル化RNAとハイブリダイズした該プローブの量 を決定する段階 を含む方法。 30.MKKの合成を調節する試薬を同定するための方法であって、 a)請求項28記載の方法の使用、および b)MKKの合成を調節する能力を有する試薬が同定されるような、MKKの合成に対す る該試薬の効果の対照との比較 を含む方法。 31.MKKの基質が、p38、JNK、ATF2、ATFa、CRE-BPa、およびc-Junのうちの1つま たはそれ以上である、請求項30記載の方法。 32.調節がMKKの合成の阻害である、請求項30記載の方法。 33.MKKを介した障害の治療に用いるための、請求項1、2、6、10、11、15、また は19のいずれか一項に記載の実質的に純粋なヒトマイトジェン活性化プロテイン キナーゼキナーゼ(MKK)ポリペプチド。 34.MKKを介した障害が、虚血性心疾患、腎不全、酸化性肝損傷、呼吸窮迫症候 群、熱および放射線による熱傷、敗血性ショック、慢性関節リウマチ、自己免疫 疾患、および炎症性疾患からなる群より選択される、請求項33記載のポリペプチ ド。 35.MKKを介する障害を治療するための医薬品の製造を目的とする、請求項33記 載のポリペプチドの使用。 36.MKKの検出に有用なキットであって、緩衝液と、請求項1、2、6、10、11、15 、または19のいずれか一項に記載のMKKポリペプチドに結合する試薬とを含み、 検査される試料が該緩衝液および該試薬と混合され、該試薬が標識される、キッ ト。 37.試薬がMKKに特異的に結合する抗体である、請求項36記載のキット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/446,083 | 1995-05-19 | ||
US08/446,083 US5804427A (en) | 1995-05-19 | 1995-05-19 | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
US08/530,950 | 1995-09-19 | ||
US08/530,950 US5736381A (en) | 1995-05-19 | 1995-09-19 | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
PCT/US1996/001078 WO1996036642A1 (en) | 1995-05-19 | 1996-01-26 | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002503946A true JP2002503946A (ja) | 2002-02-05 |
JP3948571B2 JP3948571B2 (ja) | 2007-07-25 |
Family
ID=27034496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53478796A Expired - Lifetime JP3948571B2 (ja) | 1995-05-19 | 1996-01-26 | サイトカイン、ストレス、および腫瘍性蛋白質によって活性化されるヒトプロテインキナーゼキナーゼ |
Country Status (11)
Country | Link |
---|---|
US (6) | US5736381A (ja) |
EP (2) | EP1251177A3 (ja) |
JP (1) | JP3948571B2 (ja) |
AT (1) | ATE220719T1 (ja) |
AU (1) | AU710877B2 (ja) |
CA (1) | CA2219487A1 (ja) |
DE (1) | DE69622405T2 (ja) |
DK (1) | DK0830374T3 (ja) |
ES (1) | ES2179178T3 (ja) |
PT (1) | PT830374E (ja) |
WO (1) | WO1996036642A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736381A (en) | 1995-05-19 | 1998-04-07 | Davis; Roger J. | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
US6074862A (en) * | 1995-12-20 | 2000-06-13 | Signal Pharmaceuticals Inc. | Mitogen-activated protein kinase kinase MEK6 and variants thereof |
NZ322401A (en) | 1995-12-21 | 2000-02-28 | Sunnybrook Health Science Ct | Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy, and pseudo-substrate inhibitors |
US6001622A (en) | 1995-12-21 | 1999-12-14 | Sunnybrook Health Science Centre | Integrin-linked kinase and its use |
US6699983B1 (en) | 1995-12-21 | 2004-03-02 | Sunnybrook Health Sciences Centre | Integrin-linked kinase and its uses |
US6013782A (en) * | 1995-12-21 | 2000-01-11 | Sunnybrook Health Sciences Center | Integrin-linked kinase and its uses |
US7863429B2 (en) | 1995-12-21 | 2011-01-04 | Qlt Inc. | Treatment of inflammatory diseases including psoriasis |
US6677130B1 (en) | 1996-05-20 | 2004-01-13 | Signal Pharmaceuticals, Inc. | Mitogen-activated protein kinase p38-2 and methods of use therefor |
EP0914450A1 (en) * | 1996-05-20 | 1999-05-12 | Signal Pharmaceuticals, Inc. | MITOGEN-ACTIVATED PROTEIN KINASE p38-2 AND METHODS OF USE THEREFOR |
US5948885A (en) * | 1996-05-20 | 1999-09-07 | Signal Pharmaceuticals, Inc. | Mitogen-activated protein kinase p38-2 and methods of use therefor |
AU727733B2 (en) | 1996-10-09 | 2000-12-21 | Medical Research Council | Map kinases: polypeptides, polynucleotides and uses thereof |
US6251943B1 (en) | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
US5885803A (en) | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
GB9717416D0 (en) * | 1997-08-19 | 1997-10-22 | Medical Res Council | Polypeptides,polynucleotides and uses thereof |
US6943000B2 (en) * | 1997-10-03 | 2005-09-13 | University Of Massachusetts | JNK3 modulators and methods of use |
US6492112B1 (en) | 1997-12-31 | 2002-12-10 | Chiron Corporation | Mitogen-activated protein kinase kinase 7 (MKK7) |
WO1999047686A2 (en) * | 1998-03-16 | 1999-09-23 | Cadus Pharmaceutical Corporation | Human mekk proteins, corresponding nucleic acid molecules, and uses therefor |
US6897019B1 (en) | 1998-04-17 | 2005-05-24 | Tufts College | Methods for treating and preventing insulin resistance and related disorders |
US6207458B1 (en) | 1998-05-07 | 2001-03-27 | University Of Washigton/Stowers Insitute For Medical Research | Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same |
EP1078057A2 (en) * | 1998-05-13 | 2001-02-28 | Incyte Pharmaceuticals, Inc. | Cell signaling proteins |
US6096543A (en) * | 1998-11-20 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense inhibition of human mek1 expression |
US6033910A (en) * | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
US6010906A (en) * | 1999-07-21 | 2000-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of Jun N-terminal kinase kinase-1 expression |
US6376747B1 (en) * | 1999-08-27 | 2002-04-23 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada | Plant-derived map kinase kinase |
AU1630501A (en) * | 1999-10-08 | 2001-04-23 | Superarray, Inc. | Compositions and methods for detecting protein modification and enzymatic activity |
JP2003530110A (ja) * | 2000-04-10 | 2003-10-14 | スージェン・インコーポレーテッド | 新規ヒト蛋白質キナーゼおよび蛋白質キナーゼ様酵素 |
WO2001091749A1 (en) * | 2000-06-01 | 2001-12-06 | Merck & Co., Inc. | Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors |
US6824989B1 (en) * | 2000-09-01 | 2004-11-30 | Upstate Biotechnology, Inc. | Recombinant monoclonal antibody to phosphotyrosine-containing proteins |
US6498035B1 (en) * | 2000-09-08 | 2002-12-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEKK3 expression |
EP1345603A4 (en) | 2000-12-20 | 2004-09-08 | Merck & Co Inc | P38 KINASE INHIBITORS (HALO-BENZO CARBONYL) HETEROCYCLO- FUSIONNES PHENYL |
WO2002064025A2 (en) * | 2001-02-15 | 2002-08-22 | Mount Sinai School Of Medicine Of New York University | Inhibition of atf2 activity to treat cancer |
EP2135611A1 (en) | 2001-03-01 | 2009-12-23 | Hollis-Eden Pharmaceuticals Inc. | Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy |
US20030068660A1 (en) * | 2001-09-12 | 2003-04-10 | Firestein Gary S. | Methods of ameliorating arthritis by modulating JNK signalsome activity |
GB0224013D0 (en) * | 2002-10-15 | 2002-11-27 | Oxford Glycosciences Uk Ltd | A protein involved in therapy |
US20050287565A1 (en) * | 2004-05-12 | 2005-12-29 | Merchiers Pascal G | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
WO2006029470A1 (en) * | 2004-09-17 | 2006-03-23 | Walsh, Barbara | Casual personnel recruitment method and system |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
US9061009B2 (en) * | 2007-06-08 | 2015-06-23 | University Of Massachusetts | Mixed lineage kinases and metabolic disorders |
US20120077753A1 (en) | 2009-06-25 | 2012-03-29 | Laxman Gangwani | Jnk inhibitors for use in treating spinal muscular atrophy |
US10190096B2 (en) | 2014-12-18 | 2019-01-29 | President And Fellows Of Harvard College | Methods for generating stem cell-derived β cells and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028421A1 (en) * | 1993-04-15 | 1995-10-26 | National Jewish Center For Immunology And Respiratory Medicine | Method and product for regulating cell responsiveness to external signals |
US5405941A (en) * | 1993-04-15 | 1995-04-11 | National Jewish Center For Immunology And Respiratory Medicine | MEKK protein, capable of phosphorylating MEK |
US5981265A (en) * | 1993-04-15 | 1999-11-09 | National Jewish Center For Immunology And Respiratory Medicine | Methods for regulating MEKK protein activity |
SE503628C2 (sv) * | 1994-07-05 | 1996-07-22 | Vikthygien Ab | Mätdon |
US5736381A (en) | 1995-05-19 | 1998-04-07 | Davis; Roger J. | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
-
1995
- 1995-09-19 US US08/530,950 patent/US5736381A/en not_active Expired - Lifetime
-
1996
- 1996-01-26 PT PT96905233T patent/PT830374E/pt unknown
- 1996-01-26 DE DE69622405T patent/DE69622405T2/de not_active Expired - Fee Related
- 1996-01-26 DK DK96905233T patent/DK0830374T3/da active
- 1996-01-26 JP JP53478796A patent/JP3948571B2/ja not_active Expired - Lifetime
- 1996-01-26 CA CA002219487A patent/CA2219487A1/en not_active Abandoned
- 1996-01-26 AU AU49046/96A patent/AU710877B2/en not_active Ceased
- 1996-01-26 WO PCT/US1996/001078 patent/WO1996036642A1/en active Search and Examination
- 1996-01-26 ES ES96905233T patent/ES2179178T3/es not_active Expired - Lifetime
- 1996-01-26 AT AT96905233T patent/ATE220719T1/de not_active IP Right Cessation
- 1996-01-26 EP EP02015784A patent/EP1251177A3/en not_active Withdrawn
- 1996-01-26 EP EP96905233A patent/EP0830374B1/en not_active Expired - Lifetime
-
1998
- 1998-04-07 US US09/057,009 patent/US6541605B1/en not_active Expired - Lifetime
- 1998-09-08 US US09/149,879 patent/US6174676B1/en not_active Expired - Lifetime
-
2001
- 2001-01-16 US US09/761,569 patent/US20020102691A1/en not_active Abandoned
-
2005
- 2005-04-21 US US11/111,239 patent/US20050272077A1/en not_active Abandoned
-
2008
- 2008-06-18 US US12/141,652 patent/US20090053231A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2219487A1 (en) | 1996-11-21 |
US20020102691A1 (en) | 2002-08-01 |
US5736381A (en) | 1998-04-07 |
US6174676B1 (en) | 2001-01-16 |
US20050272077A1 (en) | 2005-12-08 |
US6541605B1 (en) | 2003-04-01 |
AU4904696A (en) | 1996-11-29 |
ES2179178T3 (es) | 2003-01-16 |
PT830374E (pt) | 2002-11-29 |
DE69622405T2 (de) | 2003-03-27 |
AU710877B2 (en) | 1999-09-30 |
WO1996036642A1 (en) | 1996-11-21 |
EP0830374B1 (en) | 2002-07-17 |
EP0830374A1 (en) | 1998-03-25 |
EP0830374A4 (en) | 1998-10-07 |
EP1251177A3 (en) | 2003-04-23 |
US20090053231A1 (en) | 2009-02-26 |
EP1251177A2 (en) | 2002-10-23 |
DE69622405D1 (de) | 2002-08-22 |
ATE220719T1 (de) | 2002-08-15 |
DK0830374T3 (da) | 2002-10-28 |
JP3948571B2 (ja) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002503946A (ja) | サイトカイン、ストレス、および腫瘍性蛋白質によって活性化されるヒトプロテインキナーゼキナーゼ | |
JP4377050B2 (ja) | サイトカイン、ストレス、およびオンコプロテインに活性化されるヒト蛋白質キナーゼキナーゼ | |
WO1996036642A9 (en) | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases | |
WO2014007369A1 (ja) | Fgfr2融合遺伝子 | |
JP2008086314A (ja) | インテグリン結合キナーゼ(integrin−linkedkinase)、その阻害剤およびこれらの阻害剤を用いる医学的治療の方法、遺伝子治療ならびに偽基質阻害剤 | |
US5804427A (en) | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases | |
US7368113B2 (en) | Hormonally up-regulated, neu-tumor-associated kinase | |
Takekawa et al. | Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells | |
US7741111B2 (en) | Pregnancy, up-regulated non-ubiquitous CaM kinase | |
US10160971B2 (en) | Methods of modulating WARS2 | |
WO2000034466A1 (en) | Cervical cancer treatment | |
이현채 | The Role of Adenylyl Cyclase-Associated Protein1 (CAP1) in Transendothelial Migration of Monocytes to Promote Chronic Inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051219 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060905 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060921 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061226 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070129 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070216 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070322 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070412 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100427 Year of fee payment: 3 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100427 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110427 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120427 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120427 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130427 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130427 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140427 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |